Masaki Honda
Has grant
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Close
肝移植時の好中球動態と癌転移促進メカニズムの解析
Open Date: 2023-04-01
Close Date: 2026-03-31
Grant: Close
胆管発生と胆汁うっ滞性障害肝の病態進展におけるSOX9関連シグナル経路の機能解析
Open Date: 2021-04-01
Close Date: 2024-03-31
Grant: Close
Role of microbiome on neutrophil recruitment in tissue injury
Open Date: 2019-04-01
Close Date: 2022-03-31
Grant: Close
Grant-in-Aid for Scientific Research for the liver disease treatment that is deployed from a study of Hosotan tube metaplasia and SOX9 of biliary atresia
Open Date: 2016-04-01
Close Date: 2019-03-31
Grant: Close
Analysis of neutrophil kinetics during intestinal ischemia-reperfusion injury using two-photon excitation microscopy
Open Date: 2014-04-01
Close Date: 2017-03-31
Articles (11)
Year:
2026
Year:
2025
Year:
2025
Despite multiple techniques, portal vein (PV) inflow reconstruction during living donor liver transplantation (LDLT) for patients with biliary atresia (BA) and small-diameter PV remains a challenge. The use of PV interposition grafts has emerged as a promising therapeutic strategy to mitigate complications and reinterventions. We conducted a retrospective multicenter cohort study of patients under 3 years of age (n=85) undergoing LDLT for BA using PV interposition grafts. Our primary outcome was PV complications after LDLT, and secondary outcomes included long-term PV patency and death-censored graft survival. LDLT was performed on 85 patients. The PV diameter was 4.0±0.6 mm. Cold-stored venous allografts were used in 26 cases, donor-derived grafts in 53, and autologous in 6. The portal inflow was the PV in 38 cases, splenomesenteric confluence in 33, superior mesenteric vein in 3, and coronary vein in 1. The intraoperative PV thrombosis rate was 22.4%, and the overall PV complication rate after LDLT was 23.5% (16 PV stenoses and 4 thromboses). Multivariate analysis revealed that the use of cold-stored venous allografts predicted PV complications (53.8% vs. 10.2%; relative risk, 15.9; 95% CI: 2.9–86.2; p =0.001). Eleven patients underwent PV stent placement after LDLT with primary patency rates of 81.8% and secondary patency rates of 90.9%. The long-term patency, death-censored graft survival, and patient survival rates were 96.5%, 96.5%, and 97.6%, respectively. Portal inflow reconstruction using interposition grafts during LDLT for BA achieves favorable long-term patency and patient and graft survival outcomes. This approach has the potential to mitigate morbidity and mortality in pediatric patients with BA undergoing LDLT. Longer cold-stored venous allografts are associated with a higher risk of PV complications after LDLT.
Year:
2025
Year:
2025
Year:
2025
Aim To assess the preoperative disease characteristics and indications for living donor liver transplantation (LDLT), complications, patient survival, and prognosis after LDLT for fibropolycystic liver disease (FLD) in children. Methods We undertook a cross‐sectional survey of patients who underwent LDLT for FLD between January 2002 and December 2020. Results A total of 35 patients (22 male and 13 female individuals) with FLD were included in this study, of whom 19 (54.3%) had isolated congenital hepatic fibrosis and 16 (45.6%) had Caroli syndrome. Refractory gastrointestinal bleeding was the most frequent symptom related to the indication for LDLT, being found in 48.6% of our patients, followed by uncontrollable cholangitis and ascites. The median age at the time of LDLT was 8.1 years old. Of the 27 patients presenting with renal involvement, 13 patients required kidney transplantation (KT). Overall, the renal function after LDLT decreased regardless of renal involvement; however, patients with renal involvement had a significantly lower estimated glomerular filtration rate than those without renal involvement throughout the course of this study ( p < 0.01). The 5‐year overall patient survival rate was 97.1%. Two patients died with a median follow‐up of 8.9 years after LDLT; one died due to sepsis 2 weeks after simultaneous liver–kidney transplantation and the other committed suicide 10 years after LDLT. Conclusion The prognosis of the pediatric patients who underwent LDLT for FLD was excellent. However, an individualized treatment approach based on the status of the renal function and liver disease is important, as a certain proportion of patients require KT.
Year:
2025
Year:
2024
Background Despite early diagnosis and medical interventions, patients with methylmalonic acidemia (MMA) suffer from multi‐organ damage and recurrent metabolic decompensations. Methods We conducted the largest retrospective multi‐center cohort study so far, involving five transplant centers (NCCHD, KUH, KUHP, ATAK, and EMC), and identified all MMA patients ( n = 38) undergoing LDLT in the past two decades. Our primary outcome was patient survival, and secondary outcomes included death‐censored graft survival and posttransplant complications. Results The overall 10‐year patient survival and death‐censored graft survival rates were 92% and 97%, respectively. Patients who underwent LDLT within 2 years of MMA onset showed significantly higher 10‐year patient survival compared to those with an interval more than 2 years (100% vs. 81%, p = 0.038), although the death‐censored graft survival were not statistically different (100% vs. 93%, p = 0.22). Over the long‐term follow‐up, 14 patients (37%) experienced intellectual disability, while two patients developed neurological complications, three patients experienced renal dysfunction, and one patient had biliary anastomotic stricture. The MMA level significantly decreased from 2218.5 mmol/L preoperative to 307.5 mmol/L postoperative ( p = 0.038). Conclusions LDLT achieves favorable long‐term patient and graft survival outcomes for MMA patients. While not resulting in complete cure, our findings support the consideration of early LDLT within 2 years of disease onset. This approach holds the potential to mitigate recurrent metabolic decompensations, and preserve the long‐term renal function.
Year:
2024
Year:
2024
Year:
2024
Collaborators (3)
Lianbo Li
Kumamoto University
Shinya Okumura
Assistant Professor
Kyoto University Hospital
Taiichi Wakiya
Lecture
Jichi Medical University
Make your next move.
Prepare your application
Review drafts before you send them.